A Study of Wearable Devices to Predict Migraines

Sponsor
Mayo Clinic (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05755945
Collaborator
(none)
20
1
1
15
1.3

Study Details

Study Description

Brief Summary

The purpose of this research is to determine if data from smart devices, including heart rate and movement during sleep and wake times, will be able to track headaches and predict recurrence and exacerbations (make worse). This use of this information may in the future allow patients earlier and more effective treatments if these devices can help predict when the headaches may occur.

Condition or Disease Intervention/Treatment Phase
  • Other: eHealth Application
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Prospective Feasibility Study Evaluating the Use of Wearable Devices to Predict and Track Clinical Outcomes in Chronic Migraine
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Custom Phone eHealth Application

Subjects diagnosed with migraine headaches and have had a positive response to prevention treatments for migraine, will wear an Apple Watch whenever possible (including during sleep) and complete application questionnaires on the eHealth application daily.

Other: eHealth Application
Custom phone application that integrates data from smart watch. Subjects will complete daily "To-Do-Lists" where data will be collected on if they had a headache in the past 24 hours, severity of headache, and any analgesics used to treat the headache.

Outcome Measures

Primary Outcome Measures

  1. Percentage accuracy of fit with AUC of the ROC (receiver operating characteristics) curve (%) for headache tracking. [6 months]

    Percentage accuracy of fit with AUC of the ROC curve for factors from data collected from custom phone app integrated with smart devices to track headache frequency and severity.

Secondary Outcome Measures

  1. Percentage accuracy of fit with AUC of the ROC curve (%) for headache forecasting. [6 months]

    Percentage accuracy of fit with AUC of the ROC curve for data from custom phone app integrated with smart devices to forecast periods of increased headache likelihood.

  2. Correlation coefficients of wearable sensor data to headache frequency and severity. [6 months]

    Correlation of novel physiological clinical outcome data (e.g., time in bed, average sleep time, stand time, exercise time, move time, walking distance, running distance, estimated six-minute walk, steps per day, heart rate, heart rate variability) to monthly headache days, moderate to severe monthly headache days, analgesic use, MIDAS, and HIT-6.

  3. uMARS app quality mean score [6 months]

    Quality of the custom phone app integrated with smart watches as assessed by the validated uMARS.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18 years and older (no upper age limit defined)

  • History of chronic migraine as defined by the International Headache Society's International Classification of Headache Disorders (3rd edition).

  • Response to current preventative therapy with ≥ 50% improvement in the frequency of headache days when compared to baseline

  • 4 to 14 average number of total headache days per month during peak efficacy of preventative therapy

  • Ability to understand study procedures and to comply with them for the entire length of the study and use study devices as outlined in protocol.

  • Patient agrees to maintain a daily electronic headache diary.

  • Proficient in the use of electronic devices including Apple HomeKit and Apple Watch. - Subjects owns an iPhone with iOS 16 or later operating system installed on iPhone. Apple watch series 8 with watch OS6 or later will be provided by the study.

Exclusion Criteria:
  • Chronic daily headache with no periods of headache freedom.

  • ≥ 15 average number of headaches days per month during peak efficacy of preventative treatment.

  • Medication overuse headache as defined by the International Headache Society's International Classification of Headache Disorders (3rd edition).

  • Daily opioid use for > 3 months (e.g., hydrocodone, oxycodone, fentanyl patch) or other daily analgesic use for chronic pain disorders (e.g., NSAIDS or acetaminophen).

  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic Minnesota Rochester Minnesota United States 55905

Sponsors and Collaborators

  • Mayo Clinic

Investigators

  • Principal Investigator: Naraya Kissoon, MD, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Narayan R. Kissoon, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT05755945
Other Study ID Numbers:
  • 22-009944
First Posted:
Mar 6, 2023
Last Update Posted:
Mar 6, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 6, 2023